High-risk RMS patients, especially those who are older than 10 years of age, with an alveolar histopathology subtype, with unfavorable primary tumor sites, and with metastatic disease with bone or BM involvement could benefit from this approach, even if immunohistochemistry is not sufficiently sensitive to identify ERBB2 surface expression. This evidence concerns the gene ERBB2 and neoplasm.